Fibrogenesis in alcoholic liver disease

World Journal of Gastroenterology

Volumn 20, Issue 25, 2014, Pages 8048-8054

  Fujii, Hideki ^a   Kawada, Norifumi ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cytokine; Fibrosis; Kupffer cell; Oxidative stress; Steatohepatitis; Stellate cell

Indexed keywords

4 HYDROXYNONENAL; ACETALDEHYDE; ALPHA SMOOTH MUSCLE ACTIN; ENDOCANNABINOID; GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 1; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; METHIONINE; OSTEOPONTIN; REACTIVE OXYGEN METABOLITE; S ADENOSYLMETHIONINE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; MATRIX METALLOPROTEINASE; MUCIN 2; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; AUTACOID;

ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; ALCOHOL METABOLISM; APOPTOSIS; ARTICLE; ENDOPLASMIC RETICULUM STRESS; FIBROGENESIS; GENE; GENETIC VARIABILITY; HUMAN; KUPFFER CELL; LIPID PEROXIDATION; LIPOGENESIS; LIVER CELL; NONHUMAN; OXIDATIVE STRESS; RISK FACTOR; SIGNAL TRANSDUCTION; STEATOSIS; STELLATE CELL; GENETIC POLYMORPHISM; LIVER CIRRHOSIS; LIVER FIBROSIS; PROTEIN EXPRESSION; REVIEW; ALCOHOL LIVER CIRRHOSIS; ANIMAL; EXPERIMENTAL LIVER CIRRHOSIS; GENETIC PREDISPOSITION; GENETICS; LIPID METABOLISM; LIVER; METABOLISM; PATHOLOGY;

ANIMALS; GENETIC PREDISPOSITION TO DISEASE; HEPATIC STELLATE CELLS; HUMANS; INFLAMMATION MEDIATORS; KUPFFER CELLS; LIPID METABOLISM; LIVER; LIVER CIRRHOSIS, ALCOHOLIC; LIVER CIRRHOSIS, EXPERIMENTAL; OXIDATIVE STRESS; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84903948693     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i25.8048     Document Type: Article

References (61)

1. Schwartz JM, Reinus JF. Prevalence and natural history of alcoholic liver disease. Clin Liver Dis 2012; 16: 659-666 [PMID: 23101975 DOI: 10.1016/j.cld.2012.08.001]
2. Michitaka K, Nishiguchi S, Aoyagi Y, Hiasa Y, Tokumoto Y, Onji M. Etiology of liver cirrhosis in Japan: a nationwide survey. J Gastroenterol 2010; 45: 86-94 [PMID: 19789837 DOI: 10.1007/s00535-009-0128-5]
3. Nakamura K, Tanaka A, Takano T. The social cost of alcohol abuse in Japan. J Stud Alcohol 1993; 54: 618-625 [PMID: 8412152]
4. Altamirano J, Bataller R. Alcoholic liver disease: pathogenesis and new targets for therapy. Nat Rev Gastroenterol Hepatol 2011; 8: 491-501 [PMID: 21826088 DOI: 10.1038/nrgastro. 2011.134]
5. Crawford JM. Histologic findings in alcoholic liver disease. Clin Liver Dis 2012; 16: 699-716 [PMID: 23101978 DOI: 10.1016/j.cld.2012.08.004]
6. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008; 88: 125-172 [PMID: 18195085 DOI: 10.1152/physrev.00013.2007]
7. Kawada N. Evolution of hepatic fibrosis research. Hepatol Res 2011; 41: 199-208 [PMID: 21338451 DOI: 10.1111/j.1872-034X.2011.00776.x]
8. Elamin EE, Masclee AA, Dekker J, Jonkers DM. Ethanol metabolism and its effects on the intestinal epithelial barrier. Nutr Rev 2013; 71: 483-499 [PMID: 23815146 DOI: 10.1111/ nure.12027]
9. Mello T, Ceni E, Surrenti C, Galli A. Alcohol induced hepatic fibrosis: role of acetaldehyde. Mol Aspects Med 2008; 29: 17-21 [PMID: 18164754 DOI: 10.1016/j.mam.2007.10.001]
10. Liu Y, Brymora J, Zhang H, Smith B, Ramezani-Moghadam M, George J, Wang J. Leptin and acetaldehyde synergistically promotes αSMA expression in hepatic stellate cells by an interleukin 6-dependent mechanism. Alcohol Clin Exp Res 2011; 35: 921-928 [PMID: 21294755 DOI: 10.1111/ j.1530-0277.2010.01422.x]
11. Leung TM, Nieto N. CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease. J Hepatol 2013; 58: 395-398 [PMID: 22940046 DOI: 10.1016/j.jhep.2012.08.018]
12. Zhu H, Jia Z, Misra H, Li YR. Oxidative stress and redox signaling mechanisms of alcoholic liver disease: updated experimental and clinical evidence. J Dig Dis 2012; 13: 133-142 [PMID: 22356308 DOI: 10.1111/j.1751-2980.2011.00569.x]
13. Dey A, Cederbaum AI. Alcohol and oxidative liver injury. Hepatology 2006; 43: S63-S74 [PMID: 16447273 DOI: 10.1002/ hep.20957]
14. Albano E. Oxidative mechanisms in the pathogenesis of alcoholic liver disease. Mol Aspects Med 2008; 29: 9-16 [PMID: 18045675 DOI: 10.1016/j.mam.2007.09.004]
15. Seth D, Haber PS, Syn WK, Diehl AM, Day CP. Pathogenesis of alcohol-induced liver disease: classical concepts and recent advances. J Gastroenterol Hepatol 2011; 26: 1089-1105 [PMID: 21545524 DOI: 10.1111/j.1440-1746.2011.06756.x]
16. Smathers RL, Galligan JJ, Stewart BJ, Petersen DR. Overview of lipid peroxidation products and hepatic protein modification in alcoholic liver disease. Chem Biol Interact 2011; 192: 107-112 [PMID: 21354120 DOI: 10.1016/j.cbi.2011.02.021]
17. Nieto N. Ethanol and fish oil induce NFkappaB transactivation of the collagen alpha2(I) promoter through lipid peroxidation-driven activation of the PKC-PI3K-Akt pathway. Hepatology 2007; 45: 1433-1445 [PMID: 17538965 DOI: 10.1002/hep.21659]
18. Kharbanda KK. Methionine metabolic pathway in alcoholic liver injury. Curr Opin Clin Nutr Metab Care 2013; 16: 89-95 [PMID: 23232418 DOI: 10.1097/MCO.0b013e32835a892a]
19. Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011; 141: 1572-1585 [PMID: 21920463 DOI: 10.1053/j.gastro.2011.09.002]
20. Alkhouri N, Carter-Kent C, Feldstein AE. Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications. Expert Rev Gastroenterol Hepatol 2011; 5: 201-212 [PMID: 21476915 DOI: 10.1586/egh.11.6]
21. Petrasek J, Iracheta-Vellve A, Csak T, Satishchandran A, Kodys K, Kurt-Jones EA, Fitzgerald KA, Szabo G. STINGIRF3 pathway links endoplasmic reticulum stress with hepatocyte apoptosis in early alcoholic liver disease. Proc Natl Acad Sci USA 2013; 110: 16544-16549 [PMID: 24052526 DOI: 10.1073/pnas.1308331110]
22. Suh YG, Jeong WI. Hepatic stellate cells and innate immunity in alcoholic liver disease. World J Gastroenterol 2011; 17: 2543-2551 [PMID: 21633659 DOI: 10.3748/wjg.v17.i20.2543]
23. Lavallard VJ, Bonnafous S, Patouraux S, Saint-Paul MC, Rousseau D, Anty R, Le Marchand-Brustel Y, Tran A, Gual P. Serum markers of hepatocyte death and apoptosis are non invasive biomarkers of severe fibrosis in patients with alcoholic liver disease. PLoS One 2011; 6: e17599 [PMID: 21445263 DOI: 10.1371/journal.pone.0017599]
24. Petrasek J, Csak T, Szabo G. Toll-like receptors in liver disease. Adv Clin Chem 2013; 59: 155-201 [PMID: 23461136]
25. Gao B, Seki E, Brenner DA, Friedman S, Cohen JI, Nagy L, Szabo G, Zakhari S. Innate immunity in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 2011; 300: G516-G525 [PMID: 21252049 DOI: 10.1152/ajpgi.00537.2010]
26. Petrasek J, Dolganiuc A, Csak T, Nath B, Hritz I, Kodys K, Catalano D, Kurt-Jones E, Mandrekar P, Szabo G. Interferon regulatory factor 3 and type I interferons are protective in alcoholic liver injury in mice by way of crosstalk of parenchymal and myeloid cells. Hepatology 2011; 53: 649-660 [PMID: 21274885 DOI: 10.1002/hep.24059]
27. Jagavelu K, Routray C, Shergill U, O'Hara SP, Faubion W, Shah VH. Endothelial cell toll-like receptor 4 regulates fibrosis-associated angiogenesis in the liver. Hepatology 2010; 52: 590-601 [PMID: 20564354 DOI: 10.1002/hep.23739]
28. Yan AW, Fouts DE, Brandl J, Stärkel P, Torralba M, Schott E, Tsukamoto H, Nelson KE, Brenner DA, Schnabl B. Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology 2011; 53: 96-105 [PMID: 21254165 DOI: 10.1002/hep.24018]
29. Rao R. Endotoxemia and gut barrier dysfunction in alcoholic liver disease. Hepatology 2009; 50: 638-644 [PMID: 19575462 DOI: 10.1002/hep.23009]
30. Hartmann P, Chen P, Wang HJ, Wang L, McCole DF, Brandl K, Stärkel P, Belzer C, Hellerbrand C, Tsukamoto H, Ho SB, Schnabl B. Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice. Hepatology 2013; 58: 108-119 [PMID: 23408358 DOI: 10.1002/hep.26321]
31. Breitkopf K, Nagy LE, Beier JI, Mueller S, Weng H, Dooley S. Current experimental perspectives on the clinical progression of alcoholic liver disease. Alcohol Clin Exp Res 2009; 33: 1647-1655 [PMID: 19645734 DOI: 10.1111/ j.1530-0277.2009.01015.x]
32. Esfandiari F, Medici V, Wong DH, Jose S, Dolatshahi M, Quinlivan E, Dayal S, Lentz SR, Tsukamoto H, Zhang YH, French SW, Halsted CH. Epigenetic regulation of hepatic endoplasmic reticulum stress pathways in the ethanol-fed cystathionine beta synthase-deficient mouse. Hepatology 2010; 51: 932-941 [PMID: 19957376 DOI: 10.1002/hep.23382]
33. Peng Z, Borea PA, Varani K, Wilder T, Yee H, Chiriboga L, Blackburn MR, Azzena G, Resta G, Cronstein BN. Adenosine signaling contributes to ethanol-induced fatty liver in mice. J Clin Invest 2009; 119: 582-594 [PMID: 19221436 DOI: 10.1172/ JCI37409]
34. Robson SC, Schuppan D. Adenosine: tipping the balance towards hepatic steatosis and fibrosis. J Hepatol 2010; 52: 941-943 [PMID: 20395005 DOI: 10.1016/j.jhep.2010.02.009]
35. Trebicka J, Racz I, Siegmund SV, Cara E, Granzow M, Schierwagen R, Klein S, Wojtalla A, Hennenberg M, Huss S, Fischer HP, Heller J, Zimmer A, Sauerbruch T. Role of cannabinoid receptors in alcoholic hepatic injury: steatosis and fibrogenesis are increased in CB2 receptordeficient mice and decreased in CB1 receptor knockouts. Liver Int 2011; 31: 860-870 [PMID: 21645218 DOI: 10.1111/ j.1478-3231.2011.02496.x]
36. Sid B, Verrax J, Calderon PB. Role of AMPK activation in oxidative cell damage: Implications for alcohol-induced liver disease. Biochem Pharmacol 2013; 86: 200-209 [PMID: 23688501 DOI: 10.1016/j.bcp.2013.05.007]
37. Tam J, Liu J, Mukhopadhyay B, Cinar R, Godlewski G, Kunos G. Endocannabinoids in liver disease. Hepatology 2011; 53: 346-355 [PMID: 21254182 DOI: 10.1002/hep.24077]
38. Mallat A, Teixeira-Clerc F, Deveaux V, Manin S, Lotersztajn S. The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings. Br J Pharmacol 2011; 163: 1432-1440 [PMID: 21457226 DOI: 10.1111/j.1476-5381.2011.01397.x]
39. Jeong WI, Osei-Hyiaman D, Park O, Liu J, Bátkai S, Mukhopadhyay P, Horiguchi N, Harvey-White J, Marsicano G, Lutz B, Gao B, Kunos G. Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab 2008; 7: 227-235 [PMID: 18316028 DOI: 10.1016/j.cmet.2007.12.007]
40. Nagoshi S. Osteopontin: Versatile modulator of liver diseases. Hepatol Res 2014; 44: 22-30 [PMID: 23701387 DOI: 10.1111/hepr.12166]
41. Seth D, D'Souza El-Guindy NB, Apte M, Mari M, Dooley S, Neuman M, Haber PS, Kundu GC, Darwanto A, de Villiers WJ, Vonlaufen A, Xu Z, Phillips P, Yang S, Goldstein D, Pirola RM, Wilson JS, Moles A, Fernández A, Colell A, García-Ruiz C, Fernández-Checa JC, Meyer C, Meindl-Beinker NM. Alcohol, signaling, and ECM turnover. Alcohol Clin Exp Res 2010; 34: 4-18 [PMID: 19860812 DOI: 10.1111/ j.1530-0277.2009.01060.x]
42. Urtasun R, Lopategi A, George J, Leung TM, Lu Y, Wang X, Ge X, Fiel MI, Nieto N. Osteopontin, an oxidant stress sensitive cytokine, up-regulates collagen-I via integrin α(V)β(3) engagement and PI3K/pAkt/NFκB signaling. Hepatology 2012; 55: 594-608 [PMID: 21953216 DOI: 10.1002/hep.24701]
43. Syn WK, Choi SS, Liaskou E, Karaca GF, Agboola KM, Oo YH, Mi Z, Pereira TA, Zdanowicz M, Malladi P, Chen Y, Moylan C, Jung Y, Bhattacharya SD, Teaberry V, Omenetti A, Abdelmalek MF, Guy CD, Adams DH, Kuo PC, Michelotti GA, Whitington PF, Diehl AM. Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology 2011; 53: 106-115 [PMID: 20967826 DOI: 10.1002/hep.23998]
44. Patouraux S, Bonnafous S, Voican CS, Anty R, Saint-Paul MC, Rosenthal-Allieri MA, Agostini H, Njike M, Barri-Ova N, Naveau S, Le Marchand-Brustel Y, Veillon P, Calès P, Perlemuter G, Tran A, Gual P. The osteopontin level in liver, adipose tissue and serum is correlated with fibrosis in patients with alcoholic liver disease. PLoS One 2012; 7: e35612 [PMID: 22530059 DOI: 10.1371/journal.pone.0035612]
45. Sieghart W, Wang X, Schmid K, Pinter M, König F, Bodingbauer M, Wrba F, Rasoul-Rockenschaub S, Peck-Radosavljevic M. Osteopontin expression predicts overall survival after liver transplantation for hepatocellular carcinoma in patients beyond the Milan criteria. J Hepatol 2011; 54: 89-97 [PMID: 20970216 DOI: 10.1016/j.jhep.2010.06.030]
46. Imaeda AB, Watanabe A, Sohail MA, Mahmood S, Mohamadnejad M, Sutterwala FS, Flavell RA, Mehal WZ. Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. J Clin Invest 2009; 119: 305-314 [PMID: 19164858 DOI: 10.1172/JCI35958]
47. Miura K, Kodama Y, Inokuchi S, Schnabl B, Aoyama T, Ohnishi H, Olefsky JM, Brenner DA, Seki E. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology 2010; 139: 323-324. e7 [PMID: 20347818 DOI: 10.1053/j.gastro.2010.03.052]
48. Gieling RG, Wallace K, Han YP. Interleukin-1 participates in the progression from liver injury to fibrosis. Am J Physiol Gastrointest Liver Physiol 2009; 296: G1324-G1331 [PMID: 19342509 DOI: 10.1152/ajpgi.90564.2008]
49. Petrasek J, Dolganiuc A, Csak T, Kurt-Jones EA, Szabo G. Type I interferons protect from Toll-like receptor 9-associated liver injury and regulate IL-1 receptor antagonist in mice. Gastroenterology 2011; 140: 697-708. e4 [PMID: 20727895 DOI: 10.1053/j.gastro.2010.08.020]
50. Petrasek J, Bala S, Csak T, Lippai D, Kodys K, Menashy V, Barrieau M, Min SY, Kurt-Jones EA, Szabo G. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J Clin Invest 2012; 122: 3476-3489 [PMID: 22945633 DOI: 10.1172/JCI60777]
51. Mathews S, Gao B. Therapeutic potential of interleukin 1 inhibitors in the treatment of alcoholic liver disease. Hepatology 2013; 57: 2078-2080 [PMID: 23609413 DOI: 10.1002/ hep.26336]
52. Stickel F, Hampe J. Genetic determinants of alcoholic liver disease. Gut 2012; 61: 150-159 [PMID: 22110053 DOI: 10.1136/gutjnl-2011-301239]
53. Osterreicher CH, Halangk J, Berg T, Patsenker E, Homann N, Hellerbrand C, Seitz HK, Eurich D, Stickel F. Evaluation of the transforming growth factor beta1 codon 25 (Arg--& gt; Pro) polymorphism in alcoholic liver disease. Cytokine 2008; 42: 18-23 [PMID: 18337117 DOI: 10.1016/j.cyto.2008.02.003]
54. Stickel F, Osterreicher CH, Halangk J, Berg T, Homann N, Hellerbrand C, Patsenker E, Schneider V, Kolb A, Friess H, Schuppan D, Puhl G, Seitz HK, Leathart JL, Day CP. No role of matrixmetalloproteinase-3 genetic promoter polymorphism 1171 as a risk factor for cirrhosis in alcoholic liver disease. Alcohol Clin Exp Res 2008; 32: 959-965 [PMID: 18445105 DOI: 10.1111/j.1530-0277.2008.00654.x]
55. Krawczyk M, Müllenbach R, Weber SN, Zimmer V, Lammert F. Genome-wide association studies and genetic risk assessment of liver diseases. Nat Rev Gastroenterol Hepatol 2010; 7: 669-681 [PMID: 21045792 DOI: 10.1038/nrgastro.2010.170]
56. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, Cohen JC, Hobbs HH. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461-1465 [PMID: 18820647 DOI: 10.1038/ng.257]
57. Tian C, Stokowski RP, Kershenobich D, Ballinger DG, Hinds DA. Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet 2010; 42: 21-23 [PMID: 19946271 DOI: 10.1038/ng.488]
58. Trepo E, Guyot E, Ganne-Carrie N, Degre D, Gustot T, Franchimont D, Sutton A, Nahon P, Moreno C. PNPLA3 (rs738409 C& gt; G) is a common risk variant associated with hepatocellular carcinoma in alcoholic cirrhosis. Hepatology 2012; 55: 1307-1308 [PMID: 22162034 DOI: 10.1002/ hep.25518]
59. Trépo E, Gustot T, Degré D, Lemmers A, Verset L, Demetter P, Ouziel R, Quertinmont E, Vercruysse V, Amininejad L, Deltenre P, Le Moine O, Devière J, Franchimont D, Moreno C. Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease. J Hepatol 2011; 55: 906-912 [PMID: 21334404 DOI: 10.1016/j.jhep.2011.01.028]
60. Seth D, Daly AK, Haber PS, Day CP. Patatin-like phospholipase domain containing 3: a case in point linking genetic susceptibility for alcoholic and nonalcoholic liver disease. Hepatology 2010; 51: 1463-1465 [PMID: 20373372 DOI: 10.1002/hep.23606]
61. Burza MA, Molinaro A, Attilia ML, Rotondo C, Attilia F, Ceccanti M, Ferri F, Maldarelli F, Maffongelli A, De Santis A, Attili AF, Romeo S, Ginanni Corradini S. PNPLA3 I148M (rs738409) genetic variant and age at onset of at-risk alcohol consumption are independent risk factors for alcoholic cirrhosis. Liver Int 2014; 34: 514-520 [PMID: 24102786 DOI: 10.1111/liv.12310]